Moderna's full pipeline may fuel long-term growth.

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

March 3 (Reuters) - Moderna (MRNA.O), opens new tab has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences (ROIV.O), opens new tab, and Arbutus Biopharma (ABUS.O), opens new tab up to ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

European drug regulators recommended authorizing Moderna’s combined vaccine against Covid-19 and the flu, paving the way for the shot’s approval in the European Union at a time the company is facing ...

The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

Just over two months into 2026, Moderna has weathered a number of regulatory and financial storms that could have proven catastrophic. Moderna, which was already financially struggling, announced ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...